secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immuneering Corp (IMRX)
CIK:        0001790340
Form:       8-K
Filed at:   2026-01-07T23:59:59+00:00
Accession:  0001790340-26-000006
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Immuneering reports 64% OS at 12 months in Phase 2a pancreatic cancer trial; median OS not reached
--------------------------------------------------------------------------------

- 64% OS at 12 months (SOC 35%) in 34 first-line pancreatic cancer patients at 320 mg atebimetinib + mGnP; median OS not reached.
- Median PFS 8.5 months; 94% OS at 6 months (SOC 67%) and 83% at 9 months (SOC ~47% estimated).
- Grade ≥3 TEAEs in ≥10%: anemia (18%) and neutropenia (18%); no Grade 5 events, no new safety signals.
- Near-term milestones: Phase 3 enrollment start mid-2026; >50 patient data in H1 2026; NSCLC trial start H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1790340/000179034026000006/0001790340-26-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1790340/000179034026000006/imrx-20260107.htm
  HTML page:      https://secwatch.observer/filing/0001790340-26-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer